A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

- Results showed 100% sensitivity and reduced time to diagnosis by an estimated 65.5%, with potential to improve pathologists’ workflow in a real-world environment -Brazil-based Grupo Oncoclinicas is ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

A team of researchers in Sweden has discovered that an artificial intelligence platform is capable of accurately diagnosing prostate cancer in tissue samples, offering the potential to speed up ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...

The US Food and Drug Administration (FDA) has authorized marketing of artificial intelligence (AI) software to help pathologists detect prostate cancer. The program, called Paige Prostate, is the ...

(HealthDay)—Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a higher risk for adverse ...